Subscribe to RSS
DOI: 10.1055/s-0038-1629423
Aktive Masernimpfung bei jungen Säuglingen sicher und wirksam?
Active immunization against measles in young infants safe and effective?Publication History
Eingereicht am: 01 March 2017
angenommen am: 06 March 2017
Publication Date:
24 January 2018 (online)
Zusammenfassung
Wir berichten über drei Säuglinge im Alter unter fünf Monaten, davon ein Junge mit erhöhtem Risiko bei kardialer Grunderkrankung, die einen Tag nach Masern-Exposition mit dem Lebendimpfstoff aktiv im Sinne einer Inkubationsimpfung geimpft wurden. Die Kinder haben die Impfung gut vertragen, keine Masernerkrankung entwickelt und wiesen nach einem halben Jahr schützende Antikörper im Serum auf.
Summary
We report the cases of three infants aged between four and five months – one of whom a boy with increased risk due to cardiac disease – who have been actively immunized with measles live vaccine 1 day after being exposed to measles. The immunizations were well tolerated. None of the infants developed measles. All the three children mounted a protective antibody response as assessed six months later.
-
Literatur
- 1 Markowitz LE, Albrecht P, Rhodes P. et al Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996; 97: 53-58.
- 2 Waaijenborg S, Hahné SJ, Mollema L. et al Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis 2013; 208: 10-16.
- 3 Papania M, Baughman AL, Lee S. et al Increased susceptibility to measles in infants in the United States. Pediatrics 1999; 104: e59
- 4 RKI. Masern: Bericht zu einer nosokomialen Übertragung in einer Kinderarztpraxis. RKI: Epi Bull; 2006. 26 199-201.
- 5 Bloch AB, Orenstein WA, Ewing WM. et al Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75: 676-683.
- 6 Ständige Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut - 2016/2017. RKI: Epi Bull; 2016. 34 301-340.
- 7 World Health Organization. Measles vaccines: WHO position paper. Weekly epidemiological record 2009; 35: 349-360.
- 8 Poethko-Müller C, Mankertz A. Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS). Vaccine 2011; 29: 7949-7959.
- 9 Ständige Impfkommission am Robert Koch-Institut (RKI). Fachliche Anwendungshinweise zur Masern-Postexpositionsprophylaxe bei Risikopersonen. RKI: Epi Bull; 2017. 2 17-25.
- 10 Martins C, Garly ML, Bale C. et al Measles Virus Antibody Responses in Children Randomly Assigned to Receive Standard-Titer Edmonston-Zagreb Measles Vaccine at 4.5 and 9 Months of Age, 9 Months of Age, or 9 and 18 Months of Age. J Infect Dis 2014; 210: 693-700.
- 11 Schönberger K, Ludwig MS, Wildner M, Weissbrich B. Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009; a risk estimation. PLoS One 2013; 8: e68909